{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:31:41Z","timestamp":1792445501902,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023479","name":"CRIS Cancer Foundation","doi-asserted-by":"publisher","award":["PR_LE_2023\\u201310"],"award-info":[{"award-number":["PR_LE_2023\\u201310"]}],"id":[{"id":"10.13039\/501100023479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["MSCA-IF-894191"],"award-info":[{"award-number":["MSCA-IF-894191"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Espa\u00f1a Ministerio de Ciencia Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023\\u2013150421OB-I00"],"award-info":[{"award-number":["PID2023\\u2013150421OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007320","name":"Albert Einstein Cancer Center","doi-asserted-by":"publisher","award":["HCC202"],"award-info":[{"award-number":["HCC202"]}],"id":[{"id":"10.13039\/100007320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007320","name":"Albert Einstein Cancer Center","doi-asserted-by":"publisher","award":["UACC-893"],"award-info":[{"award-number":["UACC-893"]}],"id":[{"id":"10.13039\/100007320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007320","name":"Albert Einstein Cancer Center","doi-asserted-by":"publisher","award":["POSTD19048BOZA"],"award-info":[{"award-number":["POSTD19048BOZA"]}],"id":[{"id":"10.13039\/100007320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"Fero Foundation","doi-asserted-by":"publisher","award":["PFERO2024.02"],"award-info":[{"award-number":["PFERO2024.02"]}],"id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["819242"],"award-info":[{"award-number":["819242"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.biopha.2025.118898","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:34:21Z","timestamp":1767681261000},"page":"118898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7741-8611","authenticated-orcid":false,"given":"Roos","family":"Vincken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4276-4098","authenticated-orcid":false,"given":"Samuel T.","family":"Pasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-6618","authenticated-orcid":false,"given":"Veronica","family":"Steri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4858-2199","authenticated-orcid":false,"given":"Laura","family":"Bozal-Basterra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-8301","authenticated-orcid":false,"given":"Wilfred F.J.","family":"van IJcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkaitz","family":"Carracedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Huylebroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Moasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6033-6153","authenticated-orcid":false,"given":"Ana","family":"Ruiz-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118898_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"13","key":"10.1016\/j.biopha.2025.118898_bib2","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-18-0430","article-title":"HER2 amplification in tumors activates PI3K\/Akt Signaling Independent of HER3","volume":"78","author":"Ruiz-Saenz","year":"2018","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.biopha.2025.118898_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111338","article-title":"Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling","volume":"40","author":"Campbell","year":"2022","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.biopha.2025.118898_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.biopha.2025.118898_bib5","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118898_bib6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2017.77.1899","article-title":"Targeting HER2 by combination therapies","volume":"36","author":"Ruiz-Saenz","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118898_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med"},{"issue":"33","key":"10.1016\/j.biopha.2025.118898_bib8","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118898_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118898_bib10","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.2147\/CMAR.S194137","article-title":"Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas","volume":"11","author":"Kong","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"23","key":"10.1016\/j.biopha.2025.118898_bib11","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Nahta","year":"2005","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.biopha.2025.118898_bib12","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1158\/1078-0432.CCR-10-0410","article-title":"Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients","volume":"16","author":"Sperinde","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2025.118898_bib13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"23","key":"10.1016\/j.biopha.2025.118898_bib14","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","article-title":"Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes","volume":"15","author":"Mittendorf","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2010.01711.x","article-title":"Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer","volume":"102","author":"Mukohara","year":"2011","journal-title":"Cancer Sci."},{"issue":"24","key":"10.1016\/j.biopha.2025.118898_bib16","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","article-title":"Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)","volume":"93","author":"Lu","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.biopha.2025.118898_bib17","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-07-5962","article-title":"Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells","volume":"68","author":"Shattuck","year":"2008","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.biopha.2025.118898_bib18","doi-asserted-by":"crossref","first-page":"eabk2746","DOI":"10.1126\/sciadv.abk2746","article-title":"Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer","volume":"8","author":"Adam-Artigues","year":"2022","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.biopha.2025.118898_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.biopha.2025.118898_bib20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"Majewski","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118898_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.biopha.2025.118898_bib22","first-page":"3151","article-title":"The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides","volume":"62","author":"Motoyama","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.biopha.2025.118898_bib23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.biopha.2025.118898_bib24","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ejca.2007.08.018","article-title":"Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer","volume":"43","author":"P\u00e1lyi-Krekk","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2025.118898_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.10410","article-title":"Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance","volume":"99","author":"Price-Schiavi","year":"2002","journal-title":"Int J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118898_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102224","article-title":"A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line","volume":"4","author":"Vincken","year":"2023","journal-title":"STAR Protoc."},{"issue":"8","key":"10.1016\/j.biopha.2025.118898_bib27","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"16","key":"10.1016\/j.biopha.2025.118898_bib28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.biopha.2025.118898_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2014a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2014","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.biopha.2025.118898_bib30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"W1","key":"10.1016\/j.biopha.2025.118898_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"43","key":"10.1016\/j.biopha.2025.118898_bib32","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117058","article-title":"Identification of valid reference genes for the normalization of RT-qPCR expression studies in human breast cancer cell lines treated with and without transient transfection","volume":"10","author":"Liu","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2025.118898_bib34","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","article-title":"Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer","volume":"19","author":"Gy\u0151rffy","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"6509","key":"10.1016\/j.biopha.2025.118898_bib35","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues","volume":"369","author":"Consortium","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biopha.2025.118898_bib36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.biopha.2025.118898_bib37","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1158\/1078-0432.CCR-15-2021","article-title":"Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer","volume":"22","author":"Varadan","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2025.118898_bib38","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41416-018-0318-0","article-title":"Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit","volume":"119","author":"Triulzi","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13046-025-03276-z","article-title":"CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer","volume":"44","author":"Castagnoli","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.biopha.2025.118898_bib40","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1158\/1078-0432.CCR-07-0701","article-title":"Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the erbb receptor network","volume":"13","author":"Ritter","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.biopha.2025.118898_bib41","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","article-title":"HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2","volume":"23","author":"Hanker","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2025.118898_bib42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","article-title":"Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118898_bib44","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1073\/pnas.1014835108","article-title":"Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients","volume":"108","author":"Scaltriti","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib45","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1038\/s41467-024-50998-3","article-title":"Targeting fatty acid oxidation enhances response to HER2-targeted therapy","volume":"15","author":"Nandi","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2025.118898_bib46","first-page":"769","article-title":"Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3\/Tzb100 breast cancer cells","volume":"31","author":"Vazquez-Martin","year":"2007","journal-title":"Int J. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib47","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1038\/s41467-025-59184-5","article-title":"ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib48","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/sigtrans.2017.44","article-title":"Roles of PFKFB3 in cancer","volume":"2","author":"Shi","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2025.118898_bib49","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J. Gen. Physiol."},{"issue":"13","key":"10.1016\/j.biopha.2025.118898_bib50","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1074\/jbc.M113.529990","article-title":"Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3)","volume":"289","author":"Imbert-Fernandez","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118898_bib51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1042\/BJ20111418","article-title":"Progestins activate 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase 3 (PFKFB3) in breast cancer cells","volume":"442","author":"Novellasdemunt","year":"2012","journal-title":"Biochem J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3892\/ijo.2015.3225","article-title":"Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancer","volume":"48","author":"Han","year":"2016","journal-title":"Int J. Oncol."},{"issue":"25","key":"10.1016\/j.biopha.2025.118898_bib53","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1038\/s41388-021-01871-w","article-title":"PELP1\/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER(+) breast cancer","volume":"40","author":"Truong","year":"2021","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.biopha.2025.118898_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.400","article-title":"Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer","volume":"11","author":"Lu","year":"2021","journal-title":"Clin. Transl. Med"},{"key":"10.1016\/j.biopha.2025.118898_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114914","article-title":"PFKFB3 confers cisplatin resistance in gastric cancer by inhibiting ferroptosis through SLC7A11\/xCT dephosphorylation","volume":"159","author":"He","year":"2025","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40170-024-00366-y","article-title":"PFKFB3-dependent redox homeostasis and DNA repair support cell survival under EGFR-TKIs in non-small cell lung carcinoma","volume":"12","author":"Lypova","year":"2024","journal-title":"Cancer Metab."},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12964-025-02056-8","article-title":"Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair","volume":"23","author":"Xiao","year":"2025","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib58","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41419-025-08089-8","article-title":"PFKFB3 as a multifaceted driver and therapeutic target in castration-resistant prostate cancer","volume":"16","author":"Chen","year":"2025","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10238-024-01479-w","article-title":"Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance","volume":"24","author":"Lu","year":"2024","journal-title":"Clin. Exp. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12943-024-02165-x","article-title":"Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"23","key":"10.1016\/j.biopha.2025.118898_bib61","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41388-024-03054-9","article-title":"A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance","volume":"43","author":"Das","year":"2024","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biopha.2025.118898_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.60","article-title":"Targeting cellular metabolism to improve cancer therapeutics","volume":"4","author":"Zhao","year":"2013","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.biopha.2025.118898_bib63","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41388-020-01621-4","article-title":"Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer","volume":"40","author":"Xiao","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib64","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ijc.31868","article-title":"Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers","volume":"144","author":"Mondal","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118898_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111184","article-title":"PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ER\u03b1 stability","volume":"119","author":"Jia","year":"2024","journal-title":"Cell Signal"},{"issue":"33","key":"10.1016\/j.biopha.2025.118898_bib66","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1038\/s41388-022-02391-x","article-title":"PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma","volume":"41","author":"Thirusangu","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118898_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113557","article-title":"An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma","volume":"43","author":"Casillo","year":"2024","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.biopha.2025.118898_bib68","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000377","article-title":"A potential oncogenic role for PFKFB3 overexpression in gastric cancer progression","volume":"12","author":"Lei","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118898_bib69","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41557-024-01507-y","article-title":"Homogeneous multi-payload antibody-drug conjugates","volume":"16","author":"Journeaux","year":"2024","journal-title":"Nat. Chem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:31:42Z","timestamp":1773916302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":69,"alternative-id":["S0753332225010923"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118898","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118898"}}